You asked about the slides of ProfB and said you don’t get the nuiance of them. Well in this case, we can help. There were 3 sessions that were live streamed, MD2 was watching. I haven’t seen it yet but will be cringey no doubt, but ProfB had a 15minute slot and got through the slides in about 11-12 minutes. So have a watch and see if you thoughts match what was said.
It is hopefully educational.
It is abit of an info burst
You can also watch the debate too Choose
Hot Topic 6: B-cells in the pathogenesis of MS
However as to the idea that all drugs that work well target the memory B cell population. Here are some pictures from a couple of Posters
Natalizumab they go up as they are trapped in the blood
As for the others they go down……..Ooops my favourite MS drug didn’t quite make significance..What does that say about my favourite;-(
Also presented was a poster on vitamin D and guess what? A very small effect on memory B cells. Say not more. So here is a prediction the microbiome trials will go the same way. Let’s do a prospective study and see if microbiome drops memory B cells. Pop that in an envelope and put in your time capsule and open it after the 50+ trails that are being done in every country in every disease and the millions of pounds have been spent.
Also I was asked How does oral cladribine work? Well Duh
ProfG had a corporate poster where they showed every cell type and so they don’t put any meaning to specific cells so the message gets lost in what is an easy plausible explanation and.you get trapped into confusion. Too busy making T cell biologists happy.
And just to show it is reprodicible using another technique
Then we have Alemtuzumab
Finally Ocerlizumab. People has spent their time saying it is T cells and there was an interesting poster suggesting that CD8 CD20 dim cells accumulate in MS lesions. I would say this doesn’t point us towards CD4 Th17 as the EAEers have us believe. But what about the memory B cell. Yep you guessed it
Prof Weiner asked about the Specificity and why the Brain? You ask the same question if the talk was about T cells. Why the brain. There must be something specific in the T cell receptor, just like there must be something specific in the B cell receptor.
As for which anti-CD20 to use. Could it be ocrelizumab, rituximab, ofatumumab or ublixumab which were all presented at ECTRIMS2019 I will leave you to watch the debate.
P.S. I wonder who long Ofatumumab will be on the market…..Yep it is available for use in Cancer..not for much longer I now suspect.